Article List

WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2020> 26> 3

Volume: 26 Issue: 3

1. Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?	Page:309—311
2. Macro-aspartate aminotransferase in a healthy woman	Page:378—381
3. Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma	Page:305—308
4. Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?	Page:312—314
5. How does low-level viremia affect the prognosis of patients with chronic hepatitis B?	Page:376—377
6. Is liver biopsy still useful in the era of non-invasive tests?	Page:302—304
7. Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?	Page:315—317
8. Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis	Page:280—293
9. Management of liver diseases during the pandemic of coronavirus disease-19	Page:243—250
10. Fecal microbiota transplantation in alcohol related liver diseases	Page:294—301
11. Novel biomarkers for the management of chronic hepatitis B	Page:261—279
12. Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years	Page:318—327
13. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy	Page:251—260
14. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment	Page:328—339
15. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir	Page:364—375
16. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging	Page:340—351
17. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response	Page:352—363